KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non-Current Deferred Tax Liability (2022 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Non-Current Deferred Tax Liability for 3 consecutive years, with $23.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deferred Tax Liability rose 40.3% year-over-year to $23.3 million, compared with a TTM value of $23.3 million through Dec 2025, up 40.3%, and an annual FY2025 reading of $23.3 million, up 40.3% over the prior year.
  • Non-Current Deferred Tax Liability was $23.3 million for Q4 2025 at Recursion Pharmaceuticals, roughly flat from $23.3 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $23.8 million in Q2 2025 and bottomed at $168000.0 in Q3 2024.
  • Average Non-Current Deferred Tax Liability over 3 years is $11.8 million, with a median of $10.5 million recorded in 2023.
  • The sharpest move saw Non-Current Deferred Tax Liability crashed 91.3% in 2024, then soared 13776.19% in 2025.
  • Year by year, Non-Current Deferred Tax Liability stood at $1.3 million in 2023, then soared by 1137.86% to $16.6 million in 2024, then skyrocketed by 40.3% to $23.3 million in 2025.
  • Business Quant data shows Non-Current Deferred Tax Liability for RXRX at $23.3 million in Q4 2025, $23.3 million in Q3 2025, and $23.8 million in Q2 2025.